33.41
price down icon0.51%   -0.17
after-market Handel nachbörslich: 33.41
loading
Schlusskurs vom Vortag:
$33.58
Offen:
$33.37
24-Stunden-Volumen:
583.04K
Relative Volume:
1.00
Marktkapitalisierung:
$1.87B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
31.24
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
+0.54%
1M Leistung:
+7.22%
6M Leistung:
-14.66%
1J Leistung:
+8.65%
1-Tages-Spanne:
Value
$33.18
$34.21
1-Wochen-Bereich:
Value
$32.51
$34.21
52-Wochen-Spanne:
Value
$27.05
$40.28

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Firmenname
Supernus Pharmaceuticals Inc
Name
Telefon
301-838-2500
Name
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Mitarbeiter
674
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
SUPN's Discussions on Twitter

Vergleichen Sie SUPN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
SUPN
Supernus Pharmaceuticals Inc
33.41 1.88B 651.97M 59.71M 172.03M 1.0696
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.75 67.73B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.70 44.38B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.97B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.14 13.73B 2.99B 1.21B 1.13B 25.06

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-19 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-01-06 Eingeleitet Cantor Fitzgerald Overweight
2024-09-11 Herabstufung Piper Sandler Overweight → Neutral
2023-01-03 Fortgesetzt Jefferies Buy
2021-12-01 Fortgesetzt Jefferies Buy
2021-04-13 Hochstufung Jefferies Hold → Buy
2020-06-16 Hochstufung Piper Sandler Neutral → Overweight
2020-06-15 Fortgesetzt Jefferies Hold
2019-11-08 Herabstufung Berenberg Buy → Hold
2019-11-07 Herabstufung Stifel Buy → Hold
2019-11-06 Herabstufung Jefferies Buy → Hold
2018-11-12 Bestätigt B. Riley FBR Buy
2018-01-18 Bestätigt B. Riley FBR, Inc. Buy
2017-12-28 Bestätigt B. Riley FBR, Inc. Buy
2017-12-04 Hochstufung Janney Neutral → Buy
2017-11-08 Hochstufung Stifel Hold → Buy
2017-10-19 Eingeleitet FBR & Co. Buy
2017-09-19 Herabstufung Stifel Buy → Hold
2017-07-17 Herabstufung Piper Jaffray Overweight → Neutral
2017-07-14 Eingeleitet Janney Neutral
2017-06-01 Hochstufung Piper Jaffray Neutral → Overweight
2016-07-18 Herabstufung Northland Capital Outperform → Market Perform
2016-07-18 Herabstufung Piper Jaffray Overweight → Neutral
2016-02-08 Hochstufung Jefferies Hold → Buy
2015-11-05 Bestätigt Northland Capital Outperform
2015-10-28 Eingeleitet Northland Capital Outperform
Alle ansehen

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

pulisher
08:48 AM

Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks

08:48 AM
pulisher
08:41 AM

Supernus-Sage acquisition clears antitrust hurdle as HSR waiting period expires - Investing.com Australia

08:41 AM
pulisher
08:26 AM

Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire

08:26 AM
pulisher
08:25 AM

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga

08:25 AM
pulisher
08:25 AM

Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan

08:25 AM
pulisher
05:58 AM

Is Supernus Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio growth with strategic plans - jammulinksnews.com

05:58 AM
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Unlock powerful market analysis and alerts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Supernus Pharmaceuticals Inc.Accelerated investment success - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - 富途牛牛

Jul 26, 2025
pulisher
Jul 25, 2025

What institutions are buying Supernus Pharmaceuticals Inc. stock nowBreakthrough stock performance - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Supernus Pharmaceuticals Inc. stock priceDouble or triple returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Supernus Pharmaceuticals Inc. stockRapid wealth creation - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - FinancialContent

Jul 24, 2025
pulisher
Jul 24, 2025

What makes Supernus Pharmaceuticals Inc. stock attractive to long term investorsBreakout portfolio performance - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st

Jul 23, 2025
pulisher
Jul 23, 2025

Published on: 2025-07-23 12:28:32 - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

CNS Drug Leader Supernus Pharmaceuticals Sets Q2 2025 Earnings Call with CEO Presentation - Stock Titan

Jul 22, 2025
pulisher
Jul 19, 2025

Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox

Jul 19, 2025
pulisher
Jul 18, 2025

(SUPN) Investment Report - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 18, 2025

Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 15, 2025

Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jul 15, 2025
pulisher
Jul 11, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Jul 10, 2025

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
DEC TIMOTHY C
Senior Vice-President & CFO
Mar 10 '25
Option Exercise
0.00
3,800
0
13,636
Khattar Jack A.
President, CEO
Mar 07 '25
Option Exercise
0.00
38,640
0
992,219
Mottola Frank
SVP, Quality, GMP, Ops, IT
Mar 07 '25
Option Exercise
0.00
2,625
0
16,507
Mottola Frank
SVP, Quality, GMP, Ops, IT
Feb 26 '25
Option Exercise
0.00
5,760
0
17,683
Bhatt Padmanabh P.
Sr. VP of IP, CSO
Feb 21 '25
Option Exercise
0.00
1,650
0
11,799
Rubin Jonathan
SVP, Chief Medical Officer
Feb 21 '25
Option Exercise
0.00
1,875
0
8,780
Rubin Jonathan
SVP, Chief Medical Officer
Feb 21 '25
Sale
39.15
927
36,292
7,853
Mottola Frank
SVP, Quality, GMP, Ops, IT
Feb 21 '25
Option Exercise
0.00
1,125
0
9,576
Bhatt Padmanabh P.
Sr. VP of IP, CSO
Feb 04 '25
Option Exercise
29.61
9,477
280,614
19,626
Bhatt Padmanabh P.
Sr. VP of IP, CSO
Feb 04 '25
Sale
39.70
9,477
376,237
10,149
$72.41
price down icon 0.71%
$14.58
price down icon 2.28%
$9.26
price down icon 1.59%
drug_manufacturers_specialty_generic RDY
$14.70
price up icon 0.20%
$133.71
price up icon 1.19%
$298.14
price down icon 2.09%
Kapitalisierung:     |  Volumen (24h):